Casgevy

CRISPR Therapeutics leverages FDA-approved gene editing to target a $223B autoimmune disease market, positioning itself as the post-GLP-1 growth opportunity in biotech.

CRISPR Therapeutics holds $2B cash reserves funding gene-therapy expansion, while Casgevy sales accelerate to $116M in 2025.

Vertex Pharmaceuticals trails broader market but boasts promising pipeline candidates in kidney disease and diabetes, positioning potential recovery.

CRISPR Therapeutics stock declined 9% following a $585.2M convertible notes offering. The gene-editing company boasts FDA-approved Casgevy therapy and $1.8B in reserves but faces steep losses.

Vertex Pharmaceuticals eyes 25% stock upside to $600 as it expands beyond cystic fibrosis with new drug approvals and kidney disease candidate povetacicept.

Vertex Pharmaceuticals offers profitable gene-editing exposure versus CRISPR's pipeline-dependent model. Casgevy's slow adoption and high costs make Vertex's diversified, profitable business more attractive for risk-averse investors despite lower upside potential.

Vertex Pharmaceuticals expands beyond cystic fibrosis dominance into gene-editing treatments for blood disorders and pain management, targeting $13.1B revenue with non-CF products generating $500M+.

CRISPR Therapeutics gains FDA approval for Casgevy, its first gene-editing therapy for rare blood disorders, validating the platform with multiple pipeline candidates in development.

CRISPR Therapeutics eyes growth from Casgevy commercialization and pipeline expansion. FDA-approved gene therapy generates revenue while multiple clinical programs advance toward 2026 milestones.

CRISPR Therapeutics reports strong Q4 results with Casgevy gene therapy generating $116M revenue and 147 patient initiations, signaling accelerating adoption and market confidence.